top of page


28bio launches CNS-3D myelinated organoids to predict therapeutic efficacy
12 May 2026 Louisiana-based 28bio, a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions, has announced the launch of CNS-3D Myelinated Organoids. The ability to measure and understand the myelination process has historically relied on animal models, where myelin loss and repair occur faster and more completely than in humans, creating a translational gap that fails to reflect the slower, often incomplete remyelinat
bottom of page
